Bioequivalence Study of Levocetirizine DiHCl Tablets 5mg of Dr. Reddy's Under Fed Conditions

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01506063
Recruitment Status : Completed
First Posted : January 9, 2012
Last Update Posted : January 11, 2012
Information provided by (Responsible Party):
Dr. Reddy's Laboratories Limited

Brief Summary:
The purpose of this study is to assess the Bioequivalence of Levocetirizine DiHCl Tablets 5mg with XYZAL tablets 5 mg and to monitor clinical status, adverse events and laboratory investigations and assess relative safety and tolerance, under fed conditions.

Condition or disease Intervention/treatment Phase
Healthy Drug: Levocetirizine DiHCl Phase 1

Detailed Description:
A pivotal study to compare the Bioequivalence of Levocetirizine DiHCl Tablets 5 mg of Dr.Reddy's Laboratories Limited with XYZAL® Tablets 5 mg of UCB Farchim S.A. in healthy, human subjects under fed conditions.

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 31 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: An Open Label, Balanced, Randomized, Two-treatment, Two-period, Two-sequence, Single Oral Dose, Crossover, Bioequivalence Study of Levocetirizine DiHCl Tablets 5mg With XYZAL® Tablets 5 mg in Healthy Subjects Under Fed Conditions
Study Start Date : January 2008
Actual Primary Completion Date : January 2008
Actual Study Completion Date : January 2008

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Malnutrition

Arm Intervention/treatment
Experimental: Levocetirizine DiHCl Tablets, 5 mg
Levocetirizine DiHCl Tablets, 5 mg of Dr. Reddy's Laboratories Ltd.
Drug: Levocetirizine DiHCl
Levocetirizine DiHCl Tablets 5 mg
Other Name: XYZAL

Active Comparator: XYZAL
XYZAL Tablets 5 mg of UCB Farchim S.A.
Drug: Levocetirizine DiHCl
Levocetirizine DiHCl Tablets 5 mg
Other Name: XYZAL

Primary Outcome Measures :
  1. Bioequivalence is based on Cmax and AUC parameters [ Time Frame: 1 month ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 45 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Subjects will provide written informed consent.
  • Subjects must be healthy adults within 18-45 years of age (inclusive).
  • Body mass index of ≥18.5 kg/m2 and ≤25 kg/m2, with body weight not less than 50 kg.
  • Subjects must be of normal health as determined by medical history and physical examination performed within 15 days prior to the commencement of the dosing in Period-I.
  • Have normal ECG, chest X-Ray and vital signs and clinically non significant changes in ECG & chest X-Ray.
  • Availability of subject for the entire study period and willingness to adhere to protocol requirements as evidenced by written informed consent.
  • Subjects will be Non smokers or moderate smokers (less than 10 cigarettes a day) for at least 6 months.
  • If subject is a female volunteer and is of child bearing potential practicing an acceptable method of birth control for the duration of the study as judged by the investigator(s), such as condoms, foams, jellies, diaphragm, intrauterine device(IUD), or abstinence.

or is postmenopausal for at least 1 year. is surgically sterile (bilateral tubal ligation, bilateral oophorectomy, or hysterectomy has been performed on the subject)

•Each female subject will be given a urine pregnancy test at screening, check-in for period-1, period-2 and post study.

Exclusion Criteria:

  • Subjects incapable of understanding the informed consent.
  • Subjects with BP lesser than 90/60 mm of Hg or BP greater than or equal to 140/90 mm of Hg.
  • History of hypersensitivity or idiosyncratic reaction to Levocetirizine or other related drugs.
  • Any evidence of impairment of renal, hepatic, gastro intestinal, lung and cardiac function.
  • Subjects with a history of tuberculosis, epilepsy, asthma (during past 5 years), diabetes, psychosis or glaucoma will not be eligible for the study.
  • Regular smoker who smokes more than ten cigarettes daily or has difficulty in abstaining from smoking for the duration of each study period.
  • Subjects who have taken over the counter or prescribed medications, including any enzyme modifying drugs or any systemic medication within the past two weeks prior to prior to dosing in Period-1.
  • History of any psychiatric illness, which may impair the ability to provide written, informed consent.
  • Subject is mentally or legally incapacitated, or has a history of significant psychiatric disorder.
  • Subjects who have a history of alcohol or substance/ drug of abuse within the last 5 years.
  • Subjects with clinically significant abnormal values of laboratory parameters, including positive results of HIV, HBV, HCV, RPR tests.
  • Subjects who participated in any other clinical investigation using experimental drug or had bled more than 350 mL in the past 3 months.
  • Subjects who are unable to or likely to be non-compliant with protocol requirements or restrictions.
  • Subjects who are intolerant to venipuncture.
  • Any subject in whom Levocetirizine Dihydrochloride is contraindicated for medical reasons.
  • Female volunteers who has used implanted or injected hormonal contraceptives anytime during the 6 months prior to study or used hormonal contraceptives within 14 days before dosing.
  • Female volunteers demonstrating a positive pregnancy screen.
  • All female subjects will be screened for pregnancy at screening, check-in each study period. Subjects with positive or inconclusive results will be withdrawn from the study.
  • Female volunteers who are currently breast feeding. Female subjects who are pregnant, breast-feeding or who are likely to become pregnant during the study will not be allowed to participate. Female subjects of child bearing potential must either abstain from sexual intercourse or use a reliable barrier method (e.g. condom, IUD) of contraception during the course of the study (first dosing until last blood collection) or they will not be allowed to participate.
  • Subjects with positive urine screen for drugs of abuse at the time of admission check-in for each period will be excluded from the study.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01506063

Vimta Labs Ltd.,
Hyderabad, A.P, India, 500 051
Sponsors and Collaborators
Dr. Reddy's Laboratories Limited
Principal Investigator: Sudershan Vishwanath, MD Vimta Labs Ltd.,

Responsible Party: Dr. Reddy's Laboratories Limited Identifier: NCT01506063     History of Changes
Other Study ID Numbers: 07447/07-08
First Posted: January 9, 2012    Key Record Dates
Last Update Posted: January 11, 2012
Last Verified: January 2012

Keywords provided by Dr. Reddy's Laboratories Limited:

Additional relevant MeSH terms:
Histamine H1 Antagonists, Non-Sedating
Histamine H1 Antagonists
Histamine Antagonists
Histamine Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs
Anti-Allergic Agents